Biotech | October 18, 2021
U.S. FDA advisory committee recommends J&J booster dose
U.S. FDA to decide whether to authorize a booster dose in the coming days
U.S. FDA to decide whether to authorize a booster dose in the coming days
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Subscribe To Our Newsletter & Stay Updated
